Drug Treatments for Autism
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 475
Special Issue Editor
2. Centre for Perinatal Medicine and Health, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Interests: autism; neurodevelopment; treatment of autism; pathogenesis of autism
Special Issue Information
Dear Colleagues,
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with a prevalence of more than 1%, rising to 41% in extremely premature babies. Autism prevalence is approximately four times higher in males than females. Both environmental and genetic factors have a role in the incidence of autism. Apart from the etiological aspects of autism, treatment for the disorder is not optimal. There are several groups of autism symptoms (e.g., emotional and behavioral) which need to be treated separately, and thus there are several therapeutic approaches, such as pharmacological, educational and psychological. None of these methods are completely successful in the improvement of symptoms, especially on their own. Indeed, autism is a heterogeneous disorder which affects each person differently, and therefore people with autism have different treatment needs. In this context, this Special Issue aims to collect information about different pharmacotherapeutic approaches for autism by considering both clinical and preclinical studies to improve our knowledge on the possible pharmacotherapies currently available and identify future therapeutic targets for autism.
Dr. Maryam Ardalan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autism
- pharmacotherapy
- neurodevelopment
- pharmacological
- medication
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
